免疫系统
免疫疗法
髓系白血病
细胞毒性T细胞
医学
免疫学
髓样
CTL公司*
肿瘤科
白血病
T细胞
生物
CD8型
生物化学
体外
作者
Mengjiao Lü,Xialei Yu,Jingyan Hu,Jiajing Wang,T Wang
摘要
Abstract Background Cytotoxic T‐lymphocyte (CTL)‐mediated therapy has become the central theme of cancer immunotherapy. The present study emphasized the role of CTLs in acute myeloid leukemia (AML) and aimed to understand the role of CTLs cytogenetic markers in monitoring AML prognostic outcomes and clinical treatment responses. Methods Seurat was employed to analyze single‐cell RNA sequencing data in GSE116256. CellChat was used to detect cell–cell interactions to determine the central role of CTLs. The marker genes of CTLs were extracted and randomForestSRC was employed to construct a random forest model. The prognosis, immune checkpoint expression, immune cell infiltration, immunotherapy response and drug sensitivity of AML patients were evaluated according to the model. Results Seven types of cellular components of AML were identified in GSE116256, and CTLs radiated the most interactions with other cell types. Random forest analysis screened out six marker genes for construction of the model. The risk score calculated according to the model was positively correlated with immune score, immune cell infiltration, expression of multiple immune checkpoints and immune effect pathway. The response rate of immunotherapy was significantly higher and more sensitive to 14 drugs in high‐risk samples than in low‐risk samples, whereas low‐risk patients showed a higher sensitivity to six drugs. Conclusions The present study emphasized the central role of CTLs in cell communication and established a random forest regression model based on its cytogenetic markers, which helps to stratify the prognosis of AML, promotes the understanding of the phenotype of AML and may also guide the treatment choice of AML patients, which contributed to stratification of AML prognosis, promoted understanding of the phenotype of AML and may guide treatment selection in patients with AML.
科研通智能强力驱动
Strongly Powered by AbleSci AI